CK Life Sciences International (Holdings), Inc.

As of June 30, 2026, CK Life Sciences International (Holdings), Inc. carries a market capitalization of 5.48B, placing it among publicly traded companies globally. Its enterprise value stands at 11.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CK Life Sciences International (Holdings), Inc. has 9.61B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CK Life Sciences International (Holdings), Inc. maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, CK Life Sciences International (Holdings), Inc.'s stock has declined approximately 44.38% over the past 52 weeks. The 50-day moving average sits at 0.55, while the 200-day moving average is 0.68.

As of June 30, 2026, CK Life Sciences International (Holdings), Inc. holds 535.66M in cash and equivalents against 6.83B in total debt, resulting in a net debt position of 5.64B. Total book value stands at 3.95B, with working capital of -291.55M providing operational flexibility.

CK Life Sciences International (Holdings), Inc.'s most recent stock split took place on April 6, 2006.